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Head and neck squamous cell carcinoma (HNSCC) is a group of common cancers
characterized by a swift growth pattern, early metastasis, and dismal 5-year survival
rates. Despite the recent advances in cancer management, the multimodality approach is
not effective in eradicating HNSCC. Moreover, the clinical response to the antiangiogenic
therapy remains considerably limited in HNSCC patients, suggesting that tumor
perfusion can take place through other non-angiogenic pathways. Tumor cell-induced
angiogenesis is one of the main hallmarks of cancer. However, at the end of the
previous millennium, a new paradigm of tumor cell-associated neovascularization has
been reported in human melanoma cells. This new phenomenon, which was named
“vasculogenic mimicry” or “vascular mimicry” (VM), describes the ability of aggressively
growing tumor cells to form perfusable, matrix-rich, vessel-like networks in 3-dimensional
matrices in vitro. Similar matrix-rich VM networks were also identified in tissue samples
obtained from cancer patients. To date, myriad studies have reported intriguing features
of VM in a wide variety of cancers including HNSCC. We aim in this mini-review to
summarize the current evidence regarding the phenomenon of VM in HNSCC—from
the available detection protocols and potentially involved mechanisms, to its prognostic
value and the present limitations.
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) represents a group of common and deadly
cancers that collectively account for more than 90% of all tumors arising in the head and neck
region. It originates in the epithelial lining of the oral cavity, oropharynx, hypopharynx, and larynx
[1–3]. Of these, oral squamous cell carcinoma (OSCC) is the most common subtype of HNSCC,
where the majority of tumors are encountered in the anterior 2/3 of tongue (aka oral tongue,
OTSCC) [4]. The incidence of HNSCC has recently been increasing in many regions of the world
with a shifting trend toward women and younger populations [5, 6]. Indeed, chemical carcinogens
such as tobacco- and alcohol-derived products are the major inducers of the tumorigenesis in
HNSCC patients. Increasingly, infection with human papillomavirus (HPV), mainly by HPV-16
or HPV-18 types, is linked to HNSCC. However, HPV-positive tumors arise predominantly in the
oropharyngeal region including tonsils, base of tongue and soft palate [6–8].
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Generally, complete surgical resection of the tumor remains
the primary approach for treating patients with HNSCC.
Depending on the disease stage, surgery could be followed
by adjuvant radiotherapy with or without chemotherapy.
Unfortunately, such multimodality approach can severely impact
the quality of patient’s life, and it remains ineffective in a
considerably high number of patients [6–9]. Recently, the U.S.
Food and Drug Administration (FDA) has approved the use
of two immune checkpoint inhibitors (i.e., Pembrolizumab and
Nivolumab) for treating recurrent/metastatic HNSCC patients.
However, the overall response rates of these immunotherapeutics
were very limited ranging between 13 and 18% [10]. Despite
the remarkable progress in cancer research and management,
the 5-year survival rate of HNSCC patients remains dismal,
emphasizing the urgent need to identify more effective therapies
and clinically reliable biomarkers.
Cancer metastasis is one of the main hurdles for a successful
therapy of cancer patients, accounting for the majority of cancer-
specific deaths [11]. HNSCC is featured by high invasion rates
and most patients present with regional metastasis to cervical
lymph nodes at the time of diagnosis. Thereby, the involvement
of regional lymph nodes is one of the most important prognostic
parameters in OSCC, which can confer up to a 50% decrease
in the survival outcomes [12, 13]. Angiogenesis is an essential
process for tumor development and metastasis, which represents
an attractive target in cancer therapy. HNSCC is rich in several
angiogenesis-related factors, such as vascular endothelial growth
factor (VEGF) [14]. However, monotherapy with anti-angiogenic
agents has generally revealed a low or modest response in
HNSCC patients, suggesting that tumor perfusion can take place
independently from angiogenesis [14, 15].
In 1999, a new tumor-related angiogenic paradigm was
suggested by Maniotis and colleagues. This concept, which has
been named “vasculogenic mimicry” (VM; also referred to as
“vascular mimicry”) describes the formation of tumor-derived,
matrix-rich, vessel-like networks by aggressive melanoma cells
on a three-dimensional (3D) matrix in vitro [16, 17]. These
tumor cell-formed channels may facilitate the dissemination of
tumor cells into blood stream, and hence contribute to metastasis
and the poor survival outcomes. To date, this phenomenon
has ignited a vibrant debate among cancer researchers, which
resulted in an impressive body of reports showing intriguing
aspects of the VM in different types of cancer including HNSCC
(Figure 1) [18]. Based on the growing interest in the VM as
an attractive therapeutic and prognostic target in cancer, we
aimed in this mini-review to summarize the current knowledge
regarding VM in HNSCC.
CHARACTERIZATION OF VM IN HNSCC
The Current Practice for VM Identification,
Limitations, and New Proposals
The VM structures are currently identified in patient samples
as intratumoral red blood cell (RBC)-containing lumens that
stain positively for periodic acid-schiff (PAS) in the absence of
any endothelium-related proteins such as CD31 or CD34 [19].
FIGURE 1 | Schematic illustration of angiogenesis and vasculogenic mimicry
(VM) in the tumorigenesis of head and neck squamous cell carcinoma. (A) In
induced angiogenesis, tumor cells release potent pro-angiogenic factors that
induce the growth of inter- and intratumoral vasculature to enrich the tumor
microenvironment. (B) In the VM, the aggressively invading tumors can
generate de novo, perfusable, and matrix-rich vessel-like channels as an
alternative non-angiogenic neovascularization method. (C) These new tumor
cell-lined channels may also express a considerable levels of endothelial cell
markers (magenta color; mosaic pattern); VM channels may reach out to the
host vasculature and increase nutrient retrieval to nourish the hypoxic tumor
tissue. Ultimately, these VM channels could be utilized as a dissemination
route to facilitate distant metastasis.
However, among the limitations of this method is that PAS+
regions are not deemed sensitive to permit VM quantification,
and may also represent extracellular components that are not
necessarily relevant to the VM [20–22]. Moreover, one of the
main challenges regarding VM identification is to ascertain that
such “PAS+ regions” are truly functional vessels rather than
tumor cell-derived aggregates of glycoproteins in the tumor
microenvironment. Thus, Valdivia et al. concluded that when
identifying VM, PAS+ staining alone should be interpreted
with caution [22]. In other studies, pan-cytokeratin (CK), as a
squamous epithelial cell marker, combined with CD31/CD34,
were utilized for double-labeled immunohistochemistry to
identify the CK-positive and CD31- or CD34-negative, RBC-
containing, VM vessels in OSCC tissues [23, 24]. However,
the precise nature of these “hot spots,” whether they represent
true VM or other unrelated structures (e.g., necrotic tissues or
regressed blood vessels), remains ambiguous [19].
Importantly, a mosaic pattern of VM has been described, in
which the intratumoral VM lumens express both endothelial
and tumor cell markers. Initially, the genesis of this pattern
was inferred as connection between endothelial cells and
tumor cells in blood vessel walls [25]. However, the molecular
signature data of VM-forming tumor cells has later revealed
an upregulated expression of genes associated with “stemness,”
including endothelial cell-specific markers [26]. Apparently,
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this unique signature capacitates aggressive tumor cells to
exhibit a remarkable degree of phenotype plasticity [17, 26].
Consistent with these findings, endothelial and mesenchymal
cell-relevant markers such as CD31, VE-cadherin and vimentin
were expressed by cultured HNSCC cell lines as well as in
primary and metastatic tumor tissues [27]. Noteworthy, such
co-localization mosaic pattern of tumor/mesenchymal markers,
despite its promising prognostic value, has not been considered
when identifying the VM in HNSCC, which entails the need
for a standardized characterization protocol [19]. Additional
but less conclusive criteria were also set for detecting the
VM in HNSCC samples including the absence of intratumoral
hemorrhage, necrosis, or perivascular inflammatory cell infiltrate
in the hotspot area [28].
VM Identification in vitro
The in vitro assays showed the ability of different HNSCC cells
to form distinct “honeycomb-like” tubular networks, similar
to those formed by human umbilical vein endothelial cells
(HUVEC), when cells were cultured on Matrigel R© [27, 29–
31]. In contrast, normal human keratinocytes remained in a
dispersed single cell aggregation when cultured in the same
matrix. Likewise, tumor cells did not form any tubular networks
when they grew in confluent monolayer cultures [27, 29].
Interestingly, collagen type XVI was able through the NC11
domain to trigger vasculogenic phenotype in 2D- and 3D OSCC
cell culture conditions, implying a role of culture contents in
VM formation [31]. Furthermore, we found that the capacity
of tumor cells to generate such VM networks on 3D matrices
is not akin among all HNSCC-derived cell lines. Intriguingly,
the formation of tube-like structures in vitro was dependent on
key factors including, inter alia, the metastatic/invasive potential
of the cultured tumor cells [32]. In OTSCC, for instance, the
low-invasive SCC-25 cells failed to generate consistent tubular
networks on Matrigel R© compared with the high-invasive HSC-




Growing evidences suggest that the development of VM is
an intricate process involving various molecular mechanisms
and signaling pathways [33]. Epithelial-mesenchymal transition
(EMT) is an important developmental process whereby cells
abandon their epithelial traits and acquire mesenchymal-like
cell phenotype [34]. During EMT, cells lose their cell polarity,
forfeit their epithelial markers such as E-cadherin, and gain
mesenchymal characteristics such as N-cadherin, vimentin, and
fibronectin [35]. Indeed, there is good evidence that EMT may
promote tumor metastasis. In addition, EMT has been suggested
as a possible mechanism in the formation of VM [34, 36]. It
has been reported that siRNA knockdown of EPH receptor-A2
inhibited VM formation and tumor cell invasion by regulating
the expression of EMT-related molecules in HNSCC cell lines
[30]. In this study, inhibition of VM formation in vitro was
associated with a significant reduction in the expression of EMT-
relevant molecules such as Twist and vimentin and upregulation
of E-cadherin, claudin-4, and desmoglein-3.
Transforming growth factor beta (TGF-β) signaling is one of
the main inducers of EMT in cancer progression and metastasis
[34]. Interestingly, the exposure of cultured OTSCC cells to
TGF-β1 resulted in striking endothelial phenotypic modulations
including “cadherin switching”—marked by a robust decrease
in E-cadherin with a concurrent increase in VE-cadherin [27].
Authors concluded that such “endotheliod” phenotype possessed
by HNSCC cells may induce VM formation and facilitate tumor
progression and metastasis.
Tumor hypoxia, or a low intratumoral oxygenation, is a
pivotal microenvironmental factor that has been associated with
tumor dissemination and poor clinical outcomes in HNSCC.
Hypoxia-inducible factor-1 alpha (HIF-1α), for instance, is a key
transcriptional regulator in adaptive response to hypoxic tumor
microenvironment, which represents an interesting cancer drug
target [37, 38]. Importantly, HIF-1α has been shown to mediate
VM formation through the regulation of EMT in epithelial
ovarian cancer, where the VM-positive samples highly expressed
EMT-associatedmolecules such as Twist1, Slug, andVE-cadherin
[39]. However, to our knowledge, the role of hypoxia in the
development of VM inHNSCC patients has not been investigated
to date. This lack of evidence should be addressed in future
studies, as HIF-1α represents a strong indicator of treatment
failure and worse outcomes in HNSCC patients [37].
The EMT program has been shown to confer a strong
stemness feature to cancer cells by upregulating the expression
of the pro-angiogenic factor VEGF-A [35]. In agreement with
these data, VEGF-Awas recently found tomediate VM formation
in nasopharyngeal carcinoma (NPC) cells, suggesting another
connecting mechanism between EMT and VM formation [40].
In the same study, authors showed that VM formation was
dependent on both VEGF-A and the Epstein-Barr virus (EBV)-
encoded latent membrane protein 1 (LMP1)— a key effector
of EBV-mediated B cell transformation. Of note, knockdown
of LMP1 or VEGFR1 strongly interfered with the tubular
structures during the tubulogenesis of VM in vitro [40].
These observations suggest that EMT-related mechanisms may
underpin the development of VM in EBV-mediated NPC.
PROGNOSTIC VALUE OF VM IN HNSCC
A growing body of evidence indicates that the presence
of tumor cell-lined VM associates significantly with shorter
survival outcomes of cancer patients [41]. Thus, several studies
have investigated the feasibility to harness VM as a clinical
prognosticator in patients with HNSCC [24, 28, 40, 42, 43].
Notably, all these studies concluded that positive VM status can
predict shorter survival outcomes and dismal clinicopathological
parameters in patients with HNSCC (Table 1). In OSCC, VM-
positive status was positively correlated with more lymph node
metastasis (LNM), TNM (tumor, node, and metastasis) staging,
and larger tumor size [24, 28]. In line with these observations,
two studies with 371 laryngeal SCC cases showed a significant
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TABLE 1 | List of studies that investigated the prognostic significance of VM in HNSCC patients.
Country Tumor type Tumor site Sample
size
VM+ cases Main findings References




Patients with more VM had
poorer survival
[24]
China OSCC Tongue, gingiva, palate, tonsil 190 60
(31.57%)
VM predicted shorter survival [28]
China LSCC Larynx 203 44
(21.67%)
VM predicted poor clinical
parameters and shorter survival
[42]
China LSCC Larynx 168 37
(22.02%)




China NPC Nasopharynx 40 23
(57.50%)
VM predicted shorter survival [40]
HNSCC, Head and neck squamous cell carcinoma; OSCC, oral squamous cell carcinoma; LSCC, laryngeal squamous cell carcinoma; NPC, nasopharyngeal carcinoma; VM,
vasculogenic mimicry.
correlation between VM and the advanced tumor stages (III
and IV), LNM and TNM [42, 43]. Furthermore, Xu et al.
analyzed the prognostic significance of VM formation on the
progression-free survival of 40 patients with NPC. Interestingly,
the VM-positive group had significantly shorter survival than the
VM-negative group [40]. We showed in a recent meta-analysis
study that positive-VM status was associated with poor overall
survival (hazard ratio = 0.50; 95% confidence interval: 0.38–
0.64) in patients with SCC of head and neck or esophagus,
which remained consistent following the subgroup analysis of the
studies [19].
LYMPHATIC MIMICRY IN HNSCC
Lymphatic metastasis represents the main route of tumor cell
dissemination in HNSCC [13]. Very recently, we introduced a
potential novel mechanism of lymphatic metastasis in HNSCC—
lymphatic mimicry (LM). The LM describes a process whereby
tumor cells form CK+/lymphatic vessel endothelial hyaluronic
acid receptor 1 (LYVE-1)+ mosaic endothelial-like vessels in
cancer tissues and in vitro. The multiplex immunostaining
revealed that LM structures were negative for other lymphatic
markers such as podoplanin. Interestingly, knockdown of LYVE-
1 inhibited the capacity of tumor cells to generate consistent LM-
vessels in vitro, and reduced tumor cell metastasis in vivo [32].
These important findings call for more studies to better define
this novel, VM-related, phenomenon in the future, which could




There are myriad studies that provided interesting mechanistic
and functional insights into the concept of VM in many cancers
including HNSCC. However, these studies have concurrently
revealed the immense complexity of different overlapping
signaling pathways in the tumor microenvironment and their
plausible role in VM formation. Collectively, these findings
illuminate the significance of investigating tumor cell plasticity
in aggressive tumors such as HNSCC [17, 26, 33]. Therefore, in
addition to the aforementioned traditional method, the mosaic
tumor cell-formed lumens should be evaluated and considered
as a competent way for identifying VM in cancer tissues. Also,
owing to its key contribution to tumorigenesis and anticancer
treatment failure, there is an urgent need to investigate the role
of hypoxia in the development of VM in HNSCC.
In spite of the spirited debate ignited by this phenomenon,
some concerns were raised concerning the existence of
VM. These critics include, among others, whether it is
possible to differentiate VM structures from the intratumoral
endothelial vessels unambiguously?; and are these VM structures
representing real vessels that contribute to blood flow? [26].
Moreover, the lack of in vivo evidence for functional VM
channels, the current ambiguous methodological protocol, and
the shortage of reliable biomarkers for identifying VM represent
an unceasing challenge to date. Thus, more studies are still
needed to better characterize and understand this intriguing
phenomenon and to assess their full prognostic and therapeutic
potential in HNSCC and in other recalcitrant tumors.
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